All data are based on the daily closing price as of June 27, 2025
t
Tanvex BioPharma
6541.TW
1.80 USD
0.02
+1.12%
Overview
Last close
1.80 usd
Market cap
429.03M usd
52 week high
2.50 usd
52 week low
1.15 usd
Target price
1.8 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
154.0121
Price/Book Value
2.2531
Enterprise Value
453.66M usd
EV/Revenue
162.5029
EV/EBITDA
-9.0582
Key financials
Revenue TTM
2.79M usd
Gross Profit TTM
-495357.63 usd
EBITDA TTM
-41.81M usd
Earnings per Share
-0.27 usd
Dividend
N/A usd
Total assets
230.38M usd
Net debt
N/A usd
About
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.